Ombitasvir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ombitasvir 是一种口服生物利用度强的丙型肝炎病毒 (HCV) 非结构蛋白 5A (NS5A) 抑制剂。针对 HCV 基因型 1 至 5 的 EC50 为 0.82 至 19.3 pM，针对基因型 6a 的 EC50 为 366 pM。

Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5 and 366 pM against genotype 6a.(In Vitro):Ombitasvir is active against the genotype 2a JFH-1 replicon, with an EC50 of 0.82 pM, and the EC50s of ombitasvir are 42 pM and 68 pM against the L28 and F28 variants of this genotype 6a replicon, respectively. In GT1a, variants M28V, L31V, and H58D confers 58- to 243-fold resistance to Ombitasvir. Single variants M28T, Q30R, and Y93C/S confers 800- to 8965-fold resistance, while Y93H/N confers >40000-fold resistance to Ombitasvir.

Ombitasvir is active against the genotype 2a JFH-1 replicon, with an EC50 of 0.82 pM, and the EC50s of ombitasvir are 42 pM and 68 pM against the L28 and F28 variants of this genotype 6a replicon, respectively. In GT1a, variants M28V, L31V, and H58D confers 58- to 243-fold resistance to Ombitasvir. Single variants M28T, Q30R, and Y93C/S confers 800- to 8965-fold resistance, while Y93H/N confers >40000-fold resistance to Ombitasvir.

——

ABT-267

Microbiology/Virology

HCV

HCV NS5A

Inflammation/Immunology

hepatitis C virus (HCV) infection

1258226-87-7

894.11

C50H67N7O8

>98% (HPLC)

DMSO:33 mg/mL (36.91 mM)

COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1

L-Prolinamide22'-(((2S5S)-1-(4-(11-dimethylethyl)phenyl)-25-pyrrolidinediyl)di-41-phenylene)bis(N-(methoxycarbonyl)-L-valyl-

(-20℃)

With Ice Pack

≥ 2 years